Loading
A phase 2 trial of Zilovertamab vedotin, Cyclophosphamide, Doxorubicin, Rituximab and Prednisone in diffuse large B-cell lymphoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) is a phase 2 interventional study registered as NCT05406401 by Merck Sharp & Dohme LLC, with 60 participants enrolled, started 2022-07-14 and due to reach its primary completion in 2029-04-26. Interventions recorded: Zilovertamab Vedotin, Cyclophosphamide, Doxorubicin, Rituximab, Rituximab Biosimilar and Prednisone.
Shares Zilovertamab vedotin, Prednisone, Rituximab, Doxorubicin and the tag pipeline.
Shares Zilovertamab vedotin, Prednisone, Rituximab, Doxorubicin.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Monoclonal antibodies and the tag pipeline.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Prednisone, Rituximab, Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Doxorubicin, Cyclophosphamide, Merck & Co. (MSD), Antibody-drug conjugate (ADC) and the tag pipeline.